尸检确诊阿尔茨海默病与脑血管病脑捐献者的认知衰退轨迹
基于美国国家阿尔茨海默病协调中心(NACC)尸检确诊阿尔茨海默病(AD)的脑捐献者数据,比较合并中重度脑血管病(CBVD)与未合并者的认知和功能轨迹。共纳入2423例,其中1476例为AD+/CBVD+。合并CBVD与加速的功能和认知衰退相关,尤其在注意力、精神运动速度和工作记忆测试上。
要点
- 在尸检确诊AD的脑捐献者中,合并CBVD与加速的认知和功能衰退相关。
- AD+/CBVD+组在加工速度、工作记忆、词语流畅性、命名和CDR-SB上显示加速衰退。
- CBVD放大了AD神经病理对语义相关神经心理任务的影响。
核心结论
- 在尸检确诊AD的脑捐献者中,合并CBVD与加速的功能和认知衰退相关,尤其在注意力、精神运动速度和工作记忆的神经心理测试上。
- CBVD放大了AD神经病理对语义相关神经心理任务的影响。
- 研究结果支持合并CBVD神经病理在AD中具有显著的累加效应和更微妙的协同效应。
研究设计与样本
- 利用NACC统一数据集和神经病理数据集,比较AD+/CBVD+与AD+/CBVD-脑捐献者的认知和功能轨迹。
- 样本为2005年至2019年间尸检确诊AD(Braak分期≥3,CERAD评分≥2)且完成统一数据集评估、最近一次评估在尸检前2年内的NACC脑捐献者。
- CBVD定义为中度至重度动脉硬化或动脉粥样硬化。
- 使用倾向评分加权分离合并AD和CBVD的效应,纵向混合效应模型采用稳健贝叶斯估计。
- 主要结局为UDS神经心理测试和临床痴呆评定量表总和框(CDR-SB)评分。
主要发现
- 共2423例脑捐献者,其中1476例分类为AD+/CBVD+。
- 与AD+/CBVD-捐献者相比,AD+/CBVD+组在加工速度上显示加速衰退(β = -0.93,95% CI -1.35,-0.51,BF 130.75)。
- AD+/CBVD+组在工作记忆上显示加速衰退(β = 0.05,95% CI 0.02,0.07,BF 3.59)。
- AD+/CBVD+组在词语流畅性上显示加速衰退(β = 0.10,95% CI 0.04,0.15,BF 1.28)。
- AD+/CBVD+组在命名上显示加速衰退(β = 0.09,95% CI 0.03,0.16,BF = 0.69),在CDR-SB上显示加速衰退(β = -0.08,95% CI -0.12,-0.05,BF 18.11)。
关键数值与推荐
- 效应范围从弱(BFs <3.0)到强(BFs <150)。
- AD+/CBVD+组随时间在命名上表现更差(β = -1.04,95% CI -1.83,-0.25,BF 2.52)。
- AD+/CBVD+组随时间在词语流畅性上表现更差(β = -0.73,95% CI -1.30,-0.15,BF 1.34)。
- AD+/CBVD+组CDR-SB评分更受损(β = 0.45,95% CI 0.01,0.89,BF 0.33)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cerebrovascular disease (CBVD) is frequently comorbid with autopsy-confirmed Alzheimer disease (AD), but its contribution to the clinical presentation of AD remains unclear. We leveraged the National Alzheimer's Coordinating Center (NACC) uniform and neuropathology datasets to compare the cognitive and functional trajectories of AD+/CBVD+ and AD+/CBVD- brain donors. METHODS: The sample included NACC brain donors with autopsy-confirmed AD (Braak stage ≥3, Consortium to Establish a Registry for Alzheimer's Disease score ≥2) and complete Uniform Data Set (UDS) evaluations between 2005 and 2019, with the most recent UDS evaluation within 2 years of autopsy. CBVD was defined as moderate to severe arteriosclerosis or atherosclerosis. We used propensity score weighting to isolate the effects of comorbid AD and CBVD. This method improved the balance of covariates between the AD+/CBVD+ and AD+/CBVD- groups. Longitudinal mixed-effects models were assessed with robust bayesian estimation. UDS neuropsychological test and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scores were primary outcomes. RESULTS: Of 2,423 brain donors, 1,476 were classified as AD+/CBVD+. Compared with AD+/CVBD- donors, the AD+/CBVD+ group had accelerated decline (i.e., group × time effects) on measures of processing speed (β = -0.93, 95% CI -1.35, -0.51, Bayes factor [BF] 130.75), working memory (β = 0.05, 95% CI 0.02, 0.07, BF 3.59), verbal fluency (β = 0.10, 95% CI 0.04, 0.15, BF 1.28), naming (β = 0.09, 95% CI 0.03, 0.16, BF = 0.69), and CDR-SB (β = -0.08, 95% CI -0.12, -0.05, BF 18.11). Effects ranged from weak (BFs <3.0) to strong (BFs <150). We also found worse performance in the AD+/CBVD+ group across time on naming (β = -1.04, 95% CI -1.83, -0.25, BF 2.52) and verbal fluency (β = -0.73, 95% CI -1.30, -0.15, BF 1.34) and more impaired CDR-SB scores (β = 0.45, 95% CI 0.01, 0.89, BF 0.33). DISCUSSION: In brain donors with autopsy-confirmed AD, comorbid CBVD was associated with an accelerated functional and cognitive decline, particularly on neuropsychological tests of attention, psychomotor speed, and working memory. CBVD magnified effects of AD neuropathology on semantic-related neuropsychological tasks. Findings support a prominent additive and more subtle synergistic effect for comorbid CBVD neuropathology in AD.
引用
- Frank B, Ally M, Tripodis Y, et al. Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease. Neurology. 2022. PMID: 35444054. doi:10.1212/WNL.0000000000200304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。